Back to News
Market Impact: 0.18
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
Source: zacks.com
Market Technicals & FlowsAnalyst EstimatesHealthcare & Biotech
Aclaris Therapeutics shares surged in the latest trading session on above-average volume. However, the article cautions that recent earnings-estimate revision trends may not support further near-term price gains, creating a mixed outlook for the stock.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.05
Ticker Sentiment
ACRS0.15
More News
- Asian markets make nervous start ahead of Fed decision
- Treasury Yields Stay Elevated as Stocks Fall Before Fed
- U.S. stock futures drift higher with Fed rate hike in focus
- The Fed has to walk a fine line Wednesday. How the stock market may react, according to JPMorgan
- US 10-Year Yield Rises to Highest Since 2007 as Fed Looms
- Oil’s next test: Saudi Arabia races to restore a key safety valve for prices